Novo Nordisk, OpenAI partner to speed drug discovery

Novo Nordisk and OpenAI announced a research partnership to apply generative artificial intelligence to early-stage drug discovery. The collaboration combines Novo Nordisk's clinical and laboratory capabilities with OpenAI's large-scale machine learning models to accelerate identification and design of new therapeutic candidates.

OpenAI will provide access to its generative models and engineering support to build tools that propose molecular structures, predict biological properties and prioritize candidates for laboratory testing. Novo Nordisk will supply disease-area expertise, experimental data and laboratory capacity to test and refine AI-generated hypotheses.

Project work will be integrated into existing research pipelines at both organizations. Researchers plan to use generative methods to suggest novel small molecules and biologics, evaluate predicted activity and safety profiles in silico, and move the most promising candidates into biochemical and cellular validation workflows at Novo Nordisk.

The partners plan to jointly develop methods to fine-tune models on proprietary datasets, set performance metrics for candidate selection, and build software interfaces that let researchers review and interact with model outputs.

The agreement includes procedures to protect patient privacy and to manage sensitive research data in line with applicable law and industry standards. Intellectual property and confidentiality arrangements will govern what the partners can publish or disclose.

Company officials indicated the collaboration will test AI methods across multiple therapeutic areas and technical tasks, including target identification, molecular design and property prediction. The partners expect experimental validation to remain necessary to confirm computational predictions.

Applying machine learning to shorten discovery timelines is a growing industry trend. Any therapy developed in part with these tools will still require standard laboratory, animal and clinical testing and regulatory review before approval.